Can you describe Xolair (omalizumab) therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Xolair (Omalizumab) Therapy Overview

Xolair is a humanized monoclonal antibody that binds to circulating IgE, preventing it from attaching to mast cells and basophils, thereby blocking the allergic cascade. It is administered as a subcutaneous injection and is FDA-approved for multiple indications including moderate-to-severe allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy 1.

Mechanism of Action

Omalizumab selectively binds to free IgE in the blood, preventing IgE from binding to high-affinity receptors (FcεRI) on mast cells, basophils, and dendritic cells. This leads to:

  • Down-regulation of FcεRI receptors on these cells
  • Reduced release of inflammatory mediators (IL-4, IL-5, IL-13)
  • Decreased blood and tissue eosinophils
  • Inhibition of IgE-mediated inflammation 1

Approved Indications

Allergic Asthma

  • Patients ≥6 years with moderate-to-severe persistent allergic asthma inadequately controlled on inhaled corticosteroids
  • Requires positive skin test or in vitro reactivity to perennial aeroallergen
  • Significantly reduces exacerbation rates by 26-58% compared to placebo 2
  • Improves asthma control, reduces corticosteroid use, and enhances quality of life 3, 4

Chronic Spontaneous Urticaria (CSU)

  • Patients ≥12 years who remain symptomatic despite H1-antihistamine treatment
  • Response rates: 84% complete, 13% partial in real-world studies 5
  • Most complete responders achieve control after 1-2 doses
  • Baseline IgE levels do not predict response 5

IgE-Mediated Food Allergy

  • Patients ≥1 year for reduction of allergic reactions including anaphylaxis with accidental food exposure
  • Significantly increases tolerance to single doses of multiple food allergens 1, 6

Chronic Rhinosinusitis with Nasal Polyps

  • Adults ≥18 years as add-on maintenance therapy 1

Administration Protocol

Dosing

  • Determined by body weight and baseline serum IgE levels (for asthma)
  • Available as 75 mg, 150 mg, or 300 mg prefilled syringes/autoinjectors, or 150 mg vials requiring reconstitution 1
  • Administered subcutaneously every 2-4 weeks depending on indication and dose

Critical Safety Monitoring

Before each injection, assess:

  • Current health status and recent changes
  • Vital signs
  • Lung function (peak expiratory flow or FEV1 for asthma patients) 7

Observation periods:

  • First 3 injections: 2 hours post-injection 7
  • Subsequent injections: 30 minutes post-injection 7

This extended monitoring for initial doses is critical because anaphylaxis can occur at any time, though most reactions (78%) occur within the first 3 doses 7.

Anaphylaxis Risk Management

The risk of anaphylaxis is approximately 0.09-0.2%, but requires specific precautions 7:

Mandatory Pre-Treatment Steps

  1. Obtain informed consent discussing risks, benefits, and alternatives 7
  2. Educate patients on signs/symptoms of anaphylaxis 7
  3. Prescribe epinephrine autoinjector and ensure proper training before starting therapy 7
  4. Advise patients to carry epinephrine at all times during treatment and for 24 hours after each injection 7

Important Caveats

  • Anaphylaxis can occur after the first dose or after many doses (41 total events: 32 within first 3 doses, 9 after 4th or later dose) 7
  • Reactions can occur beyond the observation period, including up to 24 hours post-injection 7
  • Most reactions occur within 2 hours (28 of 41 events), but delayed reactions beyond 12 hours have been reported 7

Clinical Efficacy

Asthma

  • Reduces exacerbations by 26-58% versus placebo 2
  • Decreases inhaled corticosteroid requirements
  • Improves lung function and quality of life 3, 8
  • Optimal duration for evaluating efficacy: 16-32 weeks 3

Chronic Spontaneous Urticaria

  • 84% complete response rate in real-world studies 5
  • Rapid symptom control, often after 1-2 doses
  • Well-tolerated with infrequent, mild adverse events 5

Food Allergy

  • Increases threshold for allergic reactions to multiple foods
  • Reduces risk of anaphylaxis with accidental exposure 1, 6

Tolerability Profile

Generally well-tolerated with most adverse events mild to moderate 2:

  • Most common: Injection-site reactions
  • Rare but serious: Anaphylaxis (0.09-0.2%) 7
  • No evidence of increased malignancy risk with long-term use 8
  • Adverse events occur at similar frequency to placebo in clinical trials 2

Special Considerations

  • Latex allergy: The needle cap of 75 mg and 150 mg prefilled syringes contains natural rubber latex derivative; use autoinjector instead 1
  • Baseline IgE: Not required for CSU; does not predict response 5
  • Vitamin D deficiency and elevated IgE are common comorbidities but do not predict treatment response 5
  • Cost: Remains a significant barrier, though biosimilar availability may improve access 9

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.